2015-07-09T16:06:29-05:00 2014-12-31 561743537 LANGDON & COMPANY LLP 223 US HIGHWAY 70 EAST SUITE 100 GARNER NC 275294051 990 2014-01-01 208423943 CHORDOMA FOUNDATION CHOR 9198096779 PO BOX 2127 DURHAM NC 27702 JOSH SOMMER EXECUTIVE DIRECTOR 9198096779 2015-07-09 true ANTHONY T PANDISCIA P00187421 9196621001 2015-07-09 2014 2016-02-25 16:41:14Z JOSH SOMMER PO BOX 2127 DURHAM NC 27702 2026625 false X WWW.CHORDOMAFOUNDATION.ORG X 2007 NC THE MISSION OF THE CHORDOMA FOUNDATION IS TO RAPIDLY DEVELOP EFFECTIVE TREATMENTS AND ULTIMATELY A CURE FOR CHORDOMA, AND TO HELP CHORDOMA PATIENTS GET THE BEST CARE POSSIBLE. 8 7 9 45 0 1609663 2011406 7649 0 622 -163 14706 1617934 2025949 250000 870478 0 239419 368357 0 291646 422644 422585 912063 1661420 705871 364529 1676211 2379674 242483 581417 1433728 1798257 THE MISSION OF THE CHORDOMA FOUNDATION IS TO RAPIDLY DEVELOP EFFECTIVE TREATMENTS AND ULTIMATELY A CURE FOR CHORDOMA, AND TO HELP CHORDOMA PATIENTS GET THE BEST CARE POSSIBLE. false false 1201830 870478 THE CHORDOMA FOUNDATION INITIATED, FACILITATED, AND FUNDED RESEARCH AIMED AT DEVELOPING NEW AND IMPROVED TREATMENTS FOR CHORDOMA. THIS INCLUDED PERFORMING GENOMIC ANALYSIS OF CHORDOMA TUMORS, DISTRIBUTING CHORDOMA CELL LINES TO RESEARCHERS ACROSS THE WORLD, FACILITATING THE EXCHANGE OF CHORDOMA TISSUE, AND BROKERING COLLABORATIONS AMONG PHYSICIANS AND SCIENTISTS. 56096 THE CHORDOMA FOUNDATION PROVIDED ACCURATE AND TIMELY INFORMATION ABOUT CHORDOMA, AND CHORDOMA TREATMENT OPTIONS, TO CHORDOMA PATIENTS AND THEIR FAMILIES, RAISED AWARENESS ABOUT CHORDOMA AND OTHER RARE CANCERS, AND SPONSORED A PEER CONNECT PROGRAM TO SUPPORT PATIENTS IN DEALING WITH CHORDOMA. 1257926 true true false false false false false false false false true false false false false true true false false false true true false false false false false true false false false false false false false true false false false false false false false false false false false true 4 0 true 9 true false false false false false true true false false false false false false X 8 7 false false false false false false false true true false false true true true true true true true true false X X X JOSH SOMMER 9198096779 2525 MERIDIAN PKWY STE 210 DURHAM NC 27713 JOSH SOMMER PRESIDENT, E 60.00 X X 86134 0 4255 JOEL BECKMAN VICE CHAIR 8.00 X 0 0 0 HANS KEULEN DIRECTOR 15.00 X 0 0 0 PAULA SONG TREASURER 3.00 X 0 0 0 CHANDRA SEN DIRECTOR 2.00 X 0 0 0 ANDY SCHOELKOPF CHAIR 15.00 X 0 0 0 JOHN THERIEN SECRETARY 4.00 X 0 0 0 HEATHER LEE DIRECTOR 2.00 X 0 0 0 86134 4255 false false false 2011406 1959 2011406 513 513 676 -676 -676 -676 OTHER REVENUE 14706 14706 14706 2025949 14030 513 780202 780202 90276 90276 90389 29481 18659 42249 233043 76009 48111 108923 17779 5799 3670 8310 27146 8854 5604 12688 12575 571 11372 632 38531 36580 100 1851 19477 5650 113 13714 29866 5707 1542 22617 37358 6421 4221 26716 29600 9869 6168 13563 57170 22168 6382 28620 11360 1035 3662 6663 2390 808 428 1154 9153 4324 1530 3299 CONTRACT RESEARCH 121160 121160 BIOREPOSITORY 52560 52560 MISCELLANEOUS EXPENSE 1385 452 286 647 1661420 1257926 111848 291646 1074946 922559 426050 785721 53000 560710 92061 79780 21342 22368 21301 15230 6347 6071 2465 2465 1676211 2379674 123222 33519 119261 547898 242483 581417 X 1298743 1436159 134985 362098 1433728 1798257 1676211 2379674 364529 X false true X true false X 356563 584425 780659 1609663 2011406 5342716 356563 584425 780659 1609663 2011406 5342716 1797580 3545136 9615 3820 1075 622 513 15645 5358361 14706 0.66160 0.82590 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 21301 15230 6071 6071 X 2199284 187365 -14030 173335 2025949 2025949 1834755 187365 -14030 173335 1661420 1661420 SCHEDULE D, PAGE 3, PART X THE FOUNDATION EVALUATES ITS UNCERTAIN TAX POSITIONS USING THE PROVISIONS OF THE FINANCIAL ACCOUNTING STANDARDS CODIFICATION (ASC) 740-10-25, RECOGNITION OF A TAX POSITION. ACCORDINGLY, THE FOUNDATION'S POLICY IS TO RECORD A LIABILITY FOR ANY TAX POSITION TAKEN THAT IS BENEFICIAL TO THE FOUNDATION, INCLUDING ANY RELATED INTEREST AND PENALTIES, WHEN IT IS MORE LIKELY THAN NOT THE POSITION OF MANAGEMENT WITH RESPECT TO A TRANSACTION OR CLASS OF TRANSACTIONS WILL BE OVERTURNED BY A TAXING AUTHORITY UPON EXAMINATION. MANAGEMENT DOES NOT BELIEVE ANY SIGNIFICANT INCOME TAX UNCERTAINTIES EXIST AS OF DECEMBER 31, 2014 OR 2013. TAX RETURNS FILED WITHIN THE PAST THREE YEARS ARE SUBJCT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE. NO EXAMINATIONS ARE CURRENTLY BEING CONDUCTED. SCHEDULE D, PAGE 4, PART XI, LINE 2D LOSS ON SALE OF ASSET 676 RECLASS OF NEGATIVE GRANT EXPENSE -14,706 SCHEDULE D, PAGE 4, PART XII, LINE 2D LOSS ON SALE OF ASSET 676 RECLASS OF NEGATIVE GRANT EXPENSE -14,706 true EUROPE GRANTS RESEARCH 90276 90276 90276 RESEARCH 20276 WIRE TRANSFER RESEARCH 50000 WIRE TRANSFER RESEARCH 20000 WIRE TRANSFER 3 false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 2 MONITORING THE USE OF GRANT FUNDS OUTSIDE THE US IS CARRIED OUT THROUGH REGULAR REPORTING BY GRANTEE ORGANIZATIONS. SCHEDULE F, PAGE 1, PART I, LINE 3 EUROPE 90,276 0 SCHEDULE F, PAGE 5, PART V 20,276 WAS AWARDED TO LEIDEN UNIVERSITY MEDICAL CENTER IN THE NETHERLANDS TO SUPPORT THE "EUROPEAN PROSPECTIVE CHORDOMA PATIENT DATABASE" PROJECT. THE FUNDING PERIOD RUNS FEBRUARY 1, 2014 THROUGH JANUARY 31, 2015. TWO- THIRDS OF THE TOTAL GRANT AMOUNT WILL BE DISBURSED UP FRONT AND THE REMAINING ONE-THIRD OF THE TOTAL GRANT AMOUNT WILL BE DISBURSED UPON DEMONSTRATION OF SATISFACTORY PROGRESS AT THE MIDWAY POINT OF THE GRANT PERIOD. 50,000 WAS AWARDED TO MAASTRICHT UNIVERSITY IN THE NETHERLANDS TO FUND THE "IDENTIFYING AND CHARACTERIZING POTENTIAL THERAPEUTIC TARGETS IN CHORDOMA" PROJECT. THE FUNDING PERIOD RUN PARIL 1, 2014 TO MARCH 31, 2015. SIXTY- FIVE PERCENT OF THE TOTAL GRANT AMOUNT WILL BE DISBURSED UP FRONT AND THE REMAINING THIRTY-FIVE (35) OF THE TOTAL GRANT AMOUNT WILL BE DISBURSED UPON DEMONSTRATION OF SATISFACTORY PROGRESS AT THE MIDWAY POINT OF THE GRANT PERIOD. 20,000 WAS AWARDED TO THE UNIVERSITY OF ULM IN GERMANY AS AN UNRESTRICTED PRIZE TO BE USED BY DR. PETER MOLLER FOR SCIENTIFIC AND EDUCATIONAL PURPOSES. true MEMORIAL SLOAN KETTERING CANCER CTR 1275 YORK AVENUE NEW YORK NY 10065 131924236 501C3 100000 RESEARCH GRANT MASSACHUSETTS GEN HOSPITAL 100 BLOSSOM CT JACKSON 1115 BOSTON MA 02114 041564655 501C3 50000 RESEARCH GRANT DUKE UNIVERSITY MEDICAL CTR 615 DOUGLAS STREET NO 700 DURHAM NC 27705 562070036 501C3 6500 RESEARCH GRANT JOHNS HOPKINS UNIVERSITY SCH OF MED 733 N BROADWAY STE 117 BALTIMORE MD 21205 900329755 501C3 110000 RESEARCH GRANT THE BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501C3 498702 RESEARCH GRANT UNIVERSITY OF MICHIGAN 1500 E MEDICAL CENTER DRIVE ANN ARBOR MI 48109 386006309 501C3 10000 RESEARCH GRANT 6 SCHEDULE I, PAGE 1, PART I, LINE 2 MONITORING USE OF GRANT FUNDS INSIDE THE US IS CARRIED OUT THROUGH REGULAR REPORTING BY GRANTEE ORGANIZATIONS. SMITH ANDERSON LLP BOARD DIRECTOR 45155 IN-KIND LEGAL SVCS false SCHEDULE L, PART V THE FOUNDATION RECEIVED AN IN-KIND DONATION OF LEGAL SERVICES FROM SMITH ANDERSON, LLP. JOHN THERIEN, A BOARD MEMBER OF THE FOUNDATION IS ALSO A PARTNER IN THE LAW FIRM SMITH ANDERSON, LLP. FORM 990, PAGE 6, PART VI, LINE 11B FINANCIAL REPORTS AND THE FORM 990 ARE REVIEWED BY THE FOUNDATION'S EXECUTIVE DIRECTOR, BOARD CHAIR AND FINANCE COMMITTEE BEFORE BEING DISTRIBUTED TO THE FULL BOARD FOR REVIEW AND APPROVAL. FORM 990, PAGE 6, PART VI, LINE 12C EACH EMPLOYEE, DIRECTOR, OR OTHER AGENT OF THE FOUNDATION ANNUALLY SIGNS A STATEMENT THAT AFFIRMS THEY HAVE RECEIVED A COPY OF THE POLICY, READ AND UNDERSTAND THE POLICY, AGREED TO COMPLY WITH THE POLICY, AND UNDERSTAND THE FOUNDATION MUST ENGAGE PRIMARILY IN ACTIVITIES THAT ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES IN ORDER TO MAINTAIN THEIR FEDERAL TAX EXEMPTION. FORM 990, PAGE 6, PART VI, LINE 15A THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS RECOMMENDS COMPENSATION OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES THAT IS (I) WITHIN THE BUDGET APPROVED BY THE BOARD OF DIRECTORS, AND (II) COMPARABLE TO INDUSTRY NORMS FOR SIMILARLY SIZED NONPROFITS. THE BOARD OF DIRECTORS DECIDE ON COMPENSATION OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES BY VOTE. FORM 990, PAGE 6, PART VI, LINE 15B THE EXECUTIVE DIRECTOR, ALONG WITH THE BOARD OF DIRECTORS, DETERMINE THE COMPENSATION OF THE ORGANIZATION'S EMPLOYEES AFTER CAREFULLY REVIEWING THE EMPLOYEE CREDENTIALS AND THE ORGANIZATION'S BUDGET. ALL POSITIONS AND COMPENSATIONS ARE APPROVED AND FUNDED THROUGH THE ANNUAL BUDGET, WHICH REQUIRES BOARD REVIEW AND APPROVAL. IN ADDITION, PERSONNEL ISSUES MAY BE BROUGHT BEFORE THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS BY THE EXECUTIVE DIRECTOR. FORM 990, PAGE 6, PART VI, LINE 19 GOVERNING DOCUMENTS, DISCLOSURE EXPLANATION, ARTICLES OF INCORPORATION, BY-LAWS, POLICIES AND PROCEDURES MANUAL, CONFLICT OF INTEREST POLICY AND OTHER GOVERNING POLICIES, ANNUAL AUDITS AND 990'S ARE ON FILE IN THE FINANCE OFFICE, AVAILABLE ON THE FOUNDATION'S WEBSITE AND AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9 LOSS ON SALE OF ASSET 676 RECLASS OF NEGATIVE GRANT EXPENSE -14,706 LOSS ON SALE OF ASSET -676 RECLASS OF NEGATIVE GRANT EXPENSE 14,706